

Evidence dossier - Kahn Brothers Group

GetCoattail manager profile: <https://getcoattail.com/manager/kahn-brothers-group> | CIK 0001039565 | Rank #128 of 149 tracked managers by reported 13F value.

Background: Founded: 1978 | HQ: New York, New York, U.S. | Style: Graham value, long-term | Key person: Irving Kahn

Background source: <https://www.insidermonkey.com/blog/5-healthcare-stocks-kahn-brothers-is-bullish-on-485758/?singlepage=1>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-17 Reported total value: \$633M Positions: 48 Top-10 concentration: 78.7% of reported value.

Ticker	Company	Weight	Reported value
C	Citigroup Inc	18.50%	\$117M
	Bayer Ag Spons Adr	14.12%	\$89M
FLG	Flagstar Financial, Inc.	9.62%	\$61M
GOOG	Alphabet Inc Class C	6.75%	\$43M
Z	Zillow Group Inc	5.89%	\$37M
OGN	Organon & Co	5.72%	\$36M
DIS	Walt Disney	5.46%	\$35M
MRK	Merck & Co. Inc.	4.43%	\$28M
MBI	M B I A Inc	4.34%	\$27M
SEG	Seaport Entmt Group	3.86%	\$24M

2. Hypothetical 13F-clone results

Window: 2016-11-01 to 2026-10-02 (40 filings). Cumulative: +126.7% CAGR: +8.60% SPY same window: cumulative +327.1%, CAGR +15.77%. Trailing CAGR - 10Y: n/a, 5Y: +5.54%, 3Y: +7.91%, 1Y: +21.91%. Max drawdown (month-end, approximate): -30.3%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001039565-16-000013	2016-11-01	35
2016Q4	0001039565-17-000001	2017-01-31	35
2017Q1	0001039565-17-000004	2017-05-08	35
2017Q2	0001039565-17-000005	2017-08-08	34
2017Q3	0001039565-17-000009	2017-11-07	34
2017Q4	0001039565-18-000004	2018-01-25	31
2018Q1	0001039565-18-000005	2018-05-01	31

2018Q2	0001039565-18-000006	2018-08-06	31
2018Q3	0001039565-18-000007	2018-10-30	31
2018Q4	0001039565-19-000001	2019-01-29	31
2019Q1	0001039565-19-000002	2019-05-06	32
2019Q2	0001039565-19-000003	2019-08-05	44
2019Q3	0001039565-19-000008	2019-11-05	48
2019Q4	0001039565-20-000002	2020-01-27	47
2020Q1	0001039565-20-000008	2020-05-11	48
2020Q2	0001039565-20-000009	2020-08-03	47
2020Q3	0001039565-20-000010	2020-11-06	42
2020Q4	0001039565-21-000001	2021-02-11	42
2021Q1	0001039565-21-000006	2021-05-07	42
2021Q2	0001039565-21-000007	2021-08-04	43
2021Q3	0001039565-21-000008	2021-11-01	43
2021Q4	0001039565-22-000001	2022-01-25	43
2022Q1	0001039565-22-000009	2022-05-02	46
2022Q2	0001039565-22-000013	2022-08-10	45
2022Q3	0001039565-22-000014	2022-11-15	45
2022Q4	0001039565-23-000002	2023-02-15	45
2023Q1	0001039565-23-000005	2023-05-12	45
2023Q2	0001039565-23-000010	2023-08-09	43
2023Q3	0001039565-23-000013	2023-11-13	43
2023Q4	0001039565-24-000001	2024-02-13	43
2024Q1	0001039565-24-000005	2024-05-15	53
2024Q2	0001039565-24-000012	2024-08-14	52
2024Q3	0001039565-24-000013	2024-11-13	53
2024Q4	0001039565-25-000001	2025-02-14	52
2025Q1	0001039565-25-000004	2025-05-15	55
2025Q2	0001039565-25-000005	2025-08-14	50
2025Q3	0001039565-25-000006	2025-11-12	53
2025Q4	0001039565-26-000001	2026-02-12	54
2026Q1	0001039565-26-000002	2026-05-08	48
2026Q2	0001039565-26-000006	2026-08-17	48

4. Coverage and adjustments

Price coverage at the latest filing: 84.9% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.